By a News Reporter-Staff News Editor at Science Letter -- Current study results on Nanoparticles have been published. According to news reporting from Cleveland, Ohio, by NewsRx journalists, research stated, "Targeted nanoparticles are being pursued for a range of medical applications. Here we utilized targeted nanoparticles (synthetic platelets) to halt bleeding in acute trauma."
The news correspondents obtained a quote from the research from Cleveland Clinic, "One of the major questions that arises in the field is the role of surface ligand density in targeted nanoparticles' performance. We developed intravenous hemostatic nanoparticles (GRGDS-NP1) and previously demonstrated their ability to reduce bleeding following femoral artery injury and increase survival after lethal liver trauma in the rat. These nanoparticles are made from block copolymers, poly(lactic-co-glycolic acid)-b-poly L-lysine-b-poly(ethylene glycol). Surface-conjugated targeting ligand density can be tightly controlled with this system, and here we investigated the effect of varying density on hemostasis and biodistribution. We increased the targeting peptide (GRGDS) concentration 100-fold (GRGDS-NP100) and undertook an in vitro dose response study using rotational thromboelastometry, finding that GRGDS-NP100 hemostatic nanoparticles were efficacious at doses at least 10 times lower than the GRGDS-NP1. These results were recapitulated in vivo, demonstrating efficacy at eight-fold lower concentration after lethal liver trauma. 1 h survival increased to 92% compared with a scrambled peptide control, 45% (OR = 14.4, 9596 CI = [1.36, 143]), a saline control, 47% (OR = 13.5, 95% CI = [1.42, 125]), and GRGDS-NP1, 80% (OR = 1.30, n.s.)."
According to the news reporters, the research concluded: "This work demonstrates the impact of changing synthetic platelet ligand density on hemostasis and lays the foundation for methods to determine optimal ligand concentration parameters."
For more information on this research see: Tuning Ligand Density on Intravenous Hemostatic Nanoparticles Dramatically Increases Survival Following Blunt Trauma. Biomacromolecules, 2013;14(8):2790-2797. Biomacromolecules can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Biomacromolecules - www.pubs.acs.org/journal/bomaf6)
Our news journalists report that additional information may be obtained by contacting A.J. Shoffstall, Cleveland Clinic, Dept. of Gen Surg, Cleveland, OH 44195, United States. Additional authors for this research include L.M. Everhart, M.E. Varley, E.S. Soehnlen, A.M. Shick, J.S. Ustin and E.B. Lavik (see also Nanoparticles).
Keywords for this news article include: Ohio, Cleveland, United States, Nanotechnology, Emerging Technologies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC